Ensign Peak Advisors’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $11.1M | Sell |
308,092
-20,900
| -6% | -$752K | 0.02% | 446 |
|
|
2025
Q1 | $13M | Sell |
328,992
-127,025
| -28% | -$5.01M | 0.02% | 399 |
|
|
2024
Q4 | $13.7M | Hold |
456,017
| – | – | 0.02% | 392 |
|
|
2024
Q3 | $10.7M | Buy |
456,017
+385,000
| +542% | +$9.01M | 0.02% | 451 |
|
|
2024
Q2 | $1.26M | Hold |
71,017
| – | – | ﹤0.01% | 1137 |
|
|
2024
Q1 | $1.08M | Sell |
71,017
-11,893
| -14% | -$181K | ﹤0.01% | 1265 |
|
|
2023
Q4 | $1.42M | Buy |
82,910
+4,860
| +6% | +$83K | ﹤0.01% | 1120 |
|
|
2023
Q3 | $652K | Buy |
78,050
+27,000
| +53% | +$226K | ﹤0.01% | 1486 |
|
|
2023
Q2 | $1.27M | Hold |
51,050
| – | – | ﹤0.01% | 1078 |
|
|
2023
Q1 | $768K | Buy |
+51,050
| New | +$768K | ﹤0.01% | 1445 |
|
|
2022
Q4 | – | Sell |
-65,580
| Closed | -$388K | – | 2188 |
|
|
2022
Q3 | $388K | Sell |
65,580
-49,850
| -43% | -$295K | ﹤0.01% | 1587 |
|
|
2022
Q2 | $491K | Buy |
115,430
+83,880
| +266% | +$357K | ﹤0.01% | 1473 |
|
|
2022
Q1 | $300K | Hold |
31,550
| – | – | ﹤0.01% | 1756 |
|
|
2021
Q4 | $599K | Buy |
+31,550
| New | +$599K | ﹤0.01% | 1553 |
|
|
2021
Q3 | – | Sell |
-43,703
| Closed | -$1.7M | – | 1881 |
|
|
2021
Q2 | $1.7M | Hold |
43,703
| – | – | ﹤0.01% | 1214 |
|
|
2021
Q1 | $2.11M | Sell |
43,703
-25,606
| -37% | -$1.23M | ﹤0.01% | 1093 |
|
|
2020
Q4 | $3.61M | Buy |
69,309
+1,000
| +1% | +$52K | 0.01% | 746 |
|
|
2020
Q3 | $1.83M | Buy |
+68,309
| New | +$1.83M | ﹤0.01% | 1016 |
|